

CORRECTION

Open Access



Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL

G. Biolcati¹, S. Hanneken², E. I. Minder³, N. J. Neumann⁴, J. H. P. Wilson⁵, P. J. Wolgen⁶, D. J. Wright⁶ and A. J. Lloyd^{7*} 

Correction to: *Journal of Patient-Reported Outcomes* (2021) 5:65
<https://doi.org/10.1186/s41687-021-00345-7>

Following publication of the original article [1], the authors identified an error in the author name of G. Biolcati.

The incorrect author name is: G. Biolcatti

The correct author name is: G. Biolcati

The author group has been updated above and the original article [1] has been corrected.

Author details

¹Centre for Porphyrias, Istituto Dermatologico S. Gallicano - Istituti Fisioterapici Ospitalieri, Rome, Italy. ²Private Practice Empoderm, Düsseldorf, Germany. ³Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland. ⁴Department of Dermatology, Heinrich Heine University, Duesseldorf, Germany. ⁵The Department of Internal Medicine, Center of Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands. ⁶Clinuvel Pharmaceuticals Limited, Melbourne, Australia. ⁷Acaster Lloyd Consulting Ltd, London, UK.

Published online: 15 August 2021

Reference

1. Biolcati G, Hanneken S, Minder EI et al (2021) Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. *J Patient Rep Outcomes* 5:65. <https://doi.org/10.1186/s41687-021-00345-7>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1186/s41687-021-00345-7>.

*Correspondence: andrew.lloyd@acasterlloyd.com

⁷ Acaster Lloyd Consulting Ltd, London, UK

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.